DystoniaBoTXNet:新型神经网络生物标志物预测孤立性肌张力障碍肉毒毒素疗效
研究开发了深度学习算法DystoniaBoTXNet,利用3D卷积神经网络和原始脑结构MRI,在284例四种局灶性肌张力障碍患者中自动发现并检验肉毒毒素疗效的神经网络生物标志物。该算法预测肉毒毒素疗效的总体准确率为96.3%,敏感度100%,特异度86.1%,每例决策计算耗时19.2秒。
要点
- DystoniaBoTXNet基于脑结构MRI预测孤立性肌张力障碍肉毒毒素疗效,总体准确率96.3%。
- 预测敏感度100%,特异度86.1%,每例计算耗时19.2秒。
- 识别的生物标志物脑区包括顶上小叶、额下回与额中回等,与肌张力障碍病理生理及肉毒毒素中枢效应相关。
核心结论
- DystoniaBoTXNet及其治疗生物标志物具有作为客观、准确、可泛化、快速且经济有效的算法平台的高转化潜力,可增强孤立性肌张力障碍患者肉毒毒素治疗的临床决策。
研究设计与样本
- 开发了深度学习算法DystoniaBoTXNet,采用3D卷积神经网络架构和原始脑结构磁共振图像,在284例四种不同形式局灶性肌张力障碍患者中自动发现并检验肉毒毒素疗效的神经网络生物标志物。
- 纳入的四种局灶性肌张力障碍包括喉部肌张力障碍、眼睑痉挛、颈部肌张力障碍和书写痉挛。
主要发现
- DystoniaBoTXNet识别出顶上小叶、额下回与额中回、眶中回、颞下回、胼胝体、额枕下束及前丘脑辐射的聚类作为治疗生物标志物的组成部分。
- 基于其生物标志物,DystoniaBoTXNet预测孤立性肌张力障碍患者肉毒毒素疗效的总体准确率为96.3%,敏感度100%,特异度86.1%。
- 算法决策每例计算耗时19.2秒。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Isolated dystonia is characterized by abnormal, often painful, postures and repetitive movements due to sustained or intermittent involuntary muscle contractions. Botulinum toxin (BoTX) injections into the affected muscles are the first line of therapy. However, there are no objective predictive markers or standardized tests of BoTX efficacy that can be utilized for appropriate candidate selection prior to treatment initiation. METHODS: We developed a deep learning algorithm, DystoniaBoTXNet, which uses a 3D convolutional neural network architecture and raw structural brain magnetic resonance images (MRIs) to automatically discover and test a neural network biomarker of BoTX efficacy in 284 patients with 4 different forms of focal dystonia, including laryngeal dystonia, blepharospasm, cervical dystonia, and writer's cramp. RESULTS: DystoniaBoTXNet identified clusters in superior parietal lobule, inferior and middle frontal gyri, middle orbital gyrus, inferior temporal gyrus, corpus callosum, inferior fronto-occipital fasciculus, and anterior thalamic radiation as components of the treatment biomarker. These regions are known to contribute to both dystonia pathophysiology across a broad clinical spectrum of disorder and the central effects of botulinum toxin treatment. Based on its biomarker, DystoniaBoTXNet achieved an overall accuracy of 96.3%, with 100% sensitivity and 86.1% specificity, in predicting BoTX efficacy in patients with isolated dystonia. The algorithmic decision was computed in 19.2 seconds per case. INTERPRETATION: DystoniaBoTXNet and its treatment biomarker have a high translational potential as an objective, accurate, generalizable, fast, and cost-effective algorithmic platform for enhancing clinical decision making for BoTX treatment in patients with isolated dystonia. ANN NEUROL 2023;93:460-471.
引用
- Yao D, O'Flynn LC, Simonyan K, et al. DystoniaBoTXNet: Novel Neural Network Biomarker of Botulinum Toxin Efficacy in Isolated Dystonia. Ann Neurol. 2022. PMID: 36440757. doi:10.1002/ana.26558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。